Ischemic Heart Disease (IHD) Drugs Market Size was valued at USD 6.07 Bn in 2023 and is predicted to reach USD 8.46 Bn by 2031 at a 4.4% CAGR during the forecast period for 2024-2031.
Ischemic heart disease (IHD) drugs are those that treat situations where the heart does not receive enough blood, most often because the coronary arteries are too small or too clogged. Some of these medications can alleviate chest pain, lower cholesterol, reduce the chance of blood clots, and lessen the workload on the heart, all of which contribute to better heart function and a lower risk of heart attacks. The rising incidence of cardiovascular disorders is driving market growth for ischemic heart disease (IHD) drugs. An important factor driving the growth of the ischemic heart disease market is the rising prevalence of IHD.
Ischemic heart disease is a rapidly expanding industry because of the increasing global mortality rate and the high incidence of chronic disorders, which increase the risk of cardiovascular diseases. Another factor impacting the ischemic heart disease (IHD) drugs market is the recent uptick in the development of more effective medications for the condition, as well as government programs aimed at raising public knowledge about the disease and providing financial support for its diagnosis, treatment, and research. Additionally, throughout the projected time frame, the ischemic heart disease market would see lucrative prospects brought about by technical advancements and product developments.
However, the market growth is hampered by the high-cost ischemic heart disease (IHD) drugs; new IHD drugs are expensive and subject to stringent regulatory authorization. Ischemic heart disease (IHD) medication sales were hit hard by the COVID-19 pandemic, which cut off supply lines and reduced healthcare access for patients. The market growth for IHD was hindered as a result of lower rates of diagnosis and treatment due to the focus on COVID-related treatments. However, when healthcare systems started to get back on their feet, the market started to rise again because people started to pay more attention to managing chronic diseases and the growth of the ischemic heart disease (IHD) drugs industry in the coming years.
The ischemic heart disease (IHD) drugs market is segmented based on disease and drug class. Based on disease, the market is segmented into angina pectoris and myocardial infarction. By drug class, the market is segmented into anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, ACE inhibitors, ARBs, vasodilators, and antithrombotic agents.
The myocardial infarction in ischemic heart disease (IHD) drugs market is expected to hold a major global market share in 2023 because myocardial infarction is on the rise around the world, and one major reason for this is the epidemic of lifestyle-related risk factors like obesity, hypertension, and diabetes. Heart disease is more common among the elderly, which means there will be a greater need for myocardial infarction therapies in the future. The availability of medicines and the quality of life for people with myocardial infarction have both been enhanced by the development of more effective medications made possible by developments in medical technology and research.
ACE inhibitors segment is growing rapidly because of their demonstrated effectiveness in lowering blood pressure and safeguarding cardiac function, thus decreasing the likelihood of cardiovascular disasters. Also pushing for their broad use are recommendations in guidelines for individuals with significant cardiovascular risk, heart failure, and hypertension, especially in countries like the US, Germany, the UK, China, and India.
The North American ischemic heart disease (IHD) drugs market is expected to register the highest market share in revenue in the near future. It can be attributed to a large number of pharmaceutical businesses, academic institutions, and healthcare facilities in the area currently being involved in the study and creation of interventions for heart failure. So, new and improved treatments for ischemic heart disease are now available, and high and rising healthcare expenditure and an advanced healthcare infrastructure.
In addition, Asia Pacific is projected to grow rapidly in the global ischemic heart disease (IHD) drugs market due to available reimbursements, major market players associated with the treatments, and many registered clinical trials. Another element that is anticipated to assist in expanding market growth in this region is the major focus on government funding and reforms.
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 6.07 Bn |
| Revenue Forecast In 2031 | USD 8.46 Bn |
| Growth Rate CAGR | CAGR of 4.4% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Disease, By Drug Class and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Ischemic Heart Disease (IHD) Drugs Market- By Disease
Ischemic Heart Disease (IHD) Drugs Market- By Drug Class
Ischemic Heart Disease (IHD) Drugs Market- By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.